Cappello Joseph
SEC CIK 1939198 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| GNLX | GENELUX Corp | VP, Pharmaceutical Development | 318.5K | — | $154.5K | 14 | 2023-02-17 | 2026-08-31 |
Most active insiders at GNLX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Zindrick Thomas | Pres, CEO | — | $117.7K |
| 2 | Thomas John | Dir | — | $108.8K |
| 3 | Smither John W | Dir | — | $34.9K |
| 4 | Cappello Joseph | Chief Technical Off | — | $34.0K |
| 5 | Yu Yong | SVP, Clinical Development | — | $32.6K |
| 6 | Smalling Ralph | Head of Regulatory | — | $2,804 |
| 7 | Pulisic Matthew | CFO | — | — |
| 8 | Mirabelli Mary | Dir | — | — |
| 9 | Groen Eric | GC | — | — |
| 10 | Tyree James L | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 19:05 | 2026-08-31 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | S - Sale | $2.74 | -10.3K | 318.5K | -3% | -$28.1K | |
| 2026-08-04 20:20 | 2026-08-04 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | S - Sale | $2.95 | -653 | 328.7K | -0.2% | -$1,924 | |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | A - Grant | $0.00 | +174.8K | 329.4K | +113% | $0 | |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | S - Sale | $2.97 | -605 | 154.5K | -0.4% | -$1,799 | |
| 2026-03-26 | 2026-03-24 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | S - Sale | $2.42 | -906 | 155.2K | -0.6% | -$2,193 | |
| M | 2025-12-11 | 2025-08-21+ | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | S - Sale | $3.88 | -3,706 | 157.0K | -2% | -$14.4K |
| D | 2025-08-29 | 2025-08-27 | GNLX | GENELUX Corp | Cappello Joseph | Chief Technical Off | A - Grant | $0.00 | +107.5K | 159.8K | +206% | $0 |
| 2025-05-13 | 2025-05-12 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.92 | -4,737 | 52.3K | -8% | -$13.8K | |
| 2025-04-17 | 2025-03-14 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +13.3K | 57.0K | +31% | $0 | |
| D | 2024-12-20 | 2024-12-18 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +29.0K | 43.7K | +198% | $0 |
| 2024-12-18 | 2024-12-16 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $2.34 | -6,300 | 14.7K | -30% | -$14.7K | |
| M | 2024-07-08 | 2024-02-19+ | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +15.2K | 9,396 | New | $0 |
| 2023-08-22 | 2023-08-18 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | S - Sale | $23.73 | -3,265 | 5,735 | -36% | -$77.5K | |
| 2023-05-02 | 2023-02-17 | GNLX | GENELUX Corp | Cappello Joseph | VP, Pharmaceutical Development | A - Grant | $0.00 | +9,000 | 9,000 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations